Valuation: Abeona Therapeutics Inc.

Market Cap 249M 223M 205M 186M 347M 23.62B 354M 2.44B 981M 12.42B 934M 914M 39.18B P/E 2026 *
-4.43x
P/E 2027 * -21.8x
Enterprise Value 249M 223M 205M 186M 347M 23.62B 354M 2.44B 981M 12.42B 934M 914M 39.18B EV / Sales 2026 *
4.73x
EV / Sales 2027 * 2.15x
Free-Float
83.76%
Yield 2026 *
-
Yield 2027 * -
1 day-4.61%
1 week-1.14%
Current month-17.14%
1 month-17.14%
3 months-32.77%
6 months-20.33%
Current year-17.46%
1 week 4.3
Extreme 4.3
4.73
1 month 4.28
Extreme 4.28
5.16
Current year 4.23
Extreme 4.23
7.65
1 year 4
Extreme 4
7.65
3 years 3.05
Extreme 3.05
9.01
5 years 2.19
Extreme 2.19
26.5
10 years 2.19
Extreme 2.19
568.75
Manager TitleAgeSince
Chief Executive Officer 50 15/10/2021
Director of Finance/CFO 42 14/03/2022
Chief Tech/Sci/R&D Officer - 20/10/2025
Director TitleAgeSince
Director/Board Member 58 01/03/2006
Director/Board Member 64 25/03/2021
Director/Board Member 63 19/04/2021
Date Insider Type Main position Quantity % Market Cap. Importance
29/09/26 Sell

Chief Executive Officer

-19,608 0.0343%
29/09/26 Sell

General Counsel

-6,727 0.0118%
29/09/26 Sell

Executive/Senior Manager

-4,902 0.0086%
Change 5-day change 1-year change 3-year change Capi.($)
-4.61%-1.14%-14.37%+14.78% 249M
+3.19%+11.31%+67.86%+150.58% 1,263B
-0.73%+3.56%+44.51%+85.81% 658B
+1.41%+3.24%+29.22%+107.83% 521B
+0.42%+3.20%+54.15%+67.18% 391B
+2.18%+2.93%+73.30%+45.62% 369B
+1.12%+4.52%+35.30%+58.08% 307B
+6.96%+8.86%+11.27%+36.62% 290B
+1.15%+6.09%+59.59%+77.06% 252B
+3.06%+9.38%+44.11%+119.47% 212B
Average +1.10%+5.19%+40.49%+76.30% 426.22B
Weighted average by Cap. +1.19%+6.60%+50.88%+98.31%

Financials

2026 *2027 *
Net sales 52.63M 47.14M 43.36M 39.29M 73.44M 5B 74.81M 517M 208M 2.63B 198M 193M 8.29B 116M 104M 95.25M 86.3M 161M 10.98B 164M 1.14B 456M 5.77B 434M 425M 18.21B
Net income -56.16M -50.3M -46.27M -41.92M -78.36M -5.33B -79.83M -552M -221M -2.81B -211M -206M -8.85B -11.39M -10.2M -9.38M -8.5M -15.89M -1.08B -16.19M -112M -44.91M -569M -42.73M -41.82M -1.79B
Net Debt - -
Projected Income Statement - Annual - Abeona Therapeutics Inc.
Logo Abeona Therapeutics Inc.
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
Employees
226
Date Price Change Volume
30/10/26 $4.350 -4.61% 783,430
29/10/26 $4.560 +0.22% 874,334
28/10/26 $4.550 +2.25% 618,145
27/10/26 $4.450 +3.25% 663,678
26/10/26 $4.310 -2.05% 426,579
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Abeona Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.350USD
Average target price
18.88USD
Spread / Average Target
+333.91%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Abeona Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. ABEO Stock